Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 05-Nov-2017

D3Sciences

Abstract

D3Sciences has invented the Triopsy™ Edge, a superior needle biopsy device capable of collecting more tissue volume and cauterizing the excision and the pathy of entry. Our business is to develop Triopsy™ Edge into a commercial prototype, submit it to the FDA for clearance, and then to manufacture and market Triopsy™ Edge to biopsy performers and their institutions around the world. We have assured market acceptance in the United States through an additional reimbursement code available to physicians, and word of mouth socialization of Triopsy™ Edge by the Key Opinion Leaders on our Medical Advisory Board. We will field our own sales force for direct sales in the first year of shipments. We will add indirect distribution channels toward the end of the first year.

Video

Original YouTube URL: Open

Introduction Video

Additional Questions

Who is your customer?

Our buyers are institutions, such as hospitals and clinics, where biopsies are performed, with device and instrument selection by the physicians and other practitioners performing the biopsies.

What problem does this idea/product solve or what market need does it serve?

Current needle biopsy devices do not harvest enough tissue to enable the full extent of pathology tests for targeted, individualized therapy, such as immunotherapy. Estimates range, but the National Cancer Institute of the NIH estimated 20% of needle biopsies fail to yield enough tissue to return an accurate and complete diagnosis. Patients wait for next steps, doctors are uncertain of what to do, and insurers pay more while the delivery of patient care is delayed.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Triopsy™ Edge is a needle biopsy device with a protruding electro-surgery and electrocautery blade. The physician fires the Triopsy™ Edge causing the blade to move backward in a twisting motion, cutting a spiral-shaped tissue sample from the suspicious mass. In addition to collecting a larger tissue sample, Triopsy™ Edge also cauterizes the excision and the path of entry, minimizing the risk of bleeding, infection, tumor seeding, and other possible complications.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

Our team, consisting of the management team, the medical and business advisors, and the Board of Directors, have knowledge and experience in startups, medical science, biomedical devices, and needle biopsy devices. Our VP of Product Development was an engineer and product manager at two incumbent manufacturers, Bard Biopsy and Merit Medical Systems. One of our business advisors is the former head of sales for Bard Biopsy, and has experience in recruiting salespeople and doctors, as well as closing orders from hospitals and other institutions. We are poised to succeed.